Aarti Pharmalabs Limited has submitted its quarterly compliance certificate under SEBI regulations for the fourth quarter of fiscal year 2026, marking another routine regulatory filing by the pharmaceutical company.

Regulatory Compliance Filing

On April 07, 2026, aarti pharma labs filed its certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing was made simultaneously to both major stock exchanges where the company's shares are listed.

Certificate Details and Confirmation

The compliance certificate was issued by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent. The certificate confirms adherence to SEBI's depositories and participants regulations for the specified quarter.

According to the documentation, MUFG Intime confirmed that securities received from depository participants for dematerialisation during Q4 FY26 were properly processed and confirmed to the depositories within prescribed timelines. The registrar also verified that security certificates received were appropriately mutilated and cancelled after due verification.

Key Compliance Highlights

The certificate reveals several important compliance aspects:

• No dematerialisation requests were received from shareholders during the quarter ended March 31, 2026
• The certificate was issued specifically for compliance purposes at the company's request
• All regulatory procedures for handling securities and maintaining member registers were followed as per SEBI guidelines
• Prescribed timelines for processing and confirmation were maintained throughout the quarter

Corporate Governance Framework

The filing was executed by Jeevan Bhargav Mondkar, who serves as Company Secretary and Legal Head with ICSI membership number A22565. The document was digitally signed on April 07, 2026, demonstrating the company's adoption of digital compliance processes.

MUFG Intime India Private Limited, with CIN U67190MH1999PTC118368, operates from its registered address in Vikhroli, Mumbai, and continues to provide registrar services to Aarti Pharmalabs Limited from its Vapi, Gujarat operations.

Regulatory Significance

This quarterly filing represents part of the ongoing regulatory compliance framework that listed companies must maintain under SEBI regulations. The certificate ensures transparency in the handling of securities and maintains investor confidence through proper documentation of depositories and participants' activities during the reporting period.

Aarti PharmaLabs Limited has published newspaper advertisements regarding its Second 100-Day Campaign 'Saksham Niveshak' in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed BSE and NSE on April 07, 2026, about the publication of advertisements in Financial Express (English) and Loksatta-Jansatta (Gujarati) on the same date.

Campaign Overview and Regulatory Compliance

The aarti pharma labs campaign, running from April 01 to July 09, 2026, follows a directive from the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs, dated March 27, 2026. The initiative focuses on proactive shareholder engagement by updating essential records, expediting dividend processing, preventing unwarranted share transfers to the IEPFA, and facilitating direct settlement of claims by the company.

Required Documentation and KYC Updates

Shareholders must update several key details to claim their unpaid dividends and prevent transfer to IEPF:

Since dividends are payable only through electronic mode, amounts will be credited to shareholders' bank accounts only after the required information and documents are updated. Shareholders can download necessary documents from the designated portal provided by MUFG Intime India Private Limited.

Contact Information and Support

For shareholders requiring assistance during the campaign, multiple contact channels are available:

Important Deadlines and Consequences

Shareholders must submit their documents by July 09, 2026, to support the campaign's success. The company has emphasized that dividend amounts remaining unclaimed for seven consecutive years will result in the corresponding equity shares being transferred to the IEPF Authority in accordance with Ministry of Corporate Affairs notifications. Shareholders whose unclaimed dividends or shares have already been transferred to IEPF can submit the prescribed Form IEPF-5 online and send physical documents to the company or registrar as per the process outlined on the IEPF website.